NCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
Clinical Trials
10 trialsNCT02627963 2023-07-18
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT01223027 2015-12-07
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Novartis
Phase 3 Completed
NCT00492986 2014-12-30
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT00111020 2014-08-06
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT00586105 2014-04-16
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
Bayer
Phase 3 Completed
NCT00073307 2014-02-06
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Bayer
Phase 3 Completed
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT00492258 2013-08-12
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00478114 2011-08-29
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Mahidol University
Phase 3 Completed